筛查发现多种自身抗体者1型糖尿病进展风险差异大
研究基于TrialNet预防路径中1815例多种自身抗体阳性者,分析年龄、抗体类型与代谢状态对1型糖尿病进展风险的影响。结果显示年龄与风险负相关,GADA阳性风险较低而IA-2A阳性风险较高,Index60<1.0者风险显著更低,部分年长儿童和成人5年风险仅8%。
要点
- 年龄越大,多种自身抗体阳性者进展为1型糖尿病的风险越低。
- 2种抗体阳性者中,GADA阳性风险较低,IA-2A阳性风险较高。
- Index60<1.0者进展风险显著低于Index60≥1.0者。
核心结论
- 筛查发现的多种自身抗体阳性者,1型糖尿病进展风险因年龄、抗体类型和代谢状态而异。
- 相当比例的年长儿童和成人多种自身抗体阳性者5年进展风险较低。
研究设计与样本
- 队列研究分析TrialNet预防路径中1815例多种自身抗体阳性参与者,年龄12.35±9.39岁(范围1-49岁)。
- 采用Cox回归和累积发病率曲线评估1型糖尿病风险。
主要发现
- 年龄与1型糖尿病风险呈负相关(HR 0.97 [95%CI 0.96, 0.99])。
- 2种抗体阳性者中,GADA阳性者风险较低(HR 0.35 [95%CI 0.22, 0.57]),IA-2A阳性者风险较高(HR 2.82 [95%CI 1.76, 4.51])。
- IAA和GADA阳性者5年1型糖尿病风险仅17%。
- Index60<1.0者风险显著低于Index60≥1.0者(HR 0.23 [95%CI 0.19, 0.30])。
- 年龄≥12.0岁且GADA阳性、IA-2A阴性、Index60<1.0者(占12%,225/1815)5年1型糖尿病风险为8%。
临床怎么用
- 临床可根据年龄、自身抗体类型和Index60分层评估多种自身抗体阳性者1型糖尿病进展风险。
- 对于低风险年长儿童和成人,可避免过度干预,并优化预防试验的靶向人群选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. METHODS: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves were utilised in this cohort study. RESULTS: Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%. CONCLUSIONS/INTERPRETATION: Type 1 diabetes risk varies substantially according to age, autoantibody type and metabolic status in individuals screened for mAbs. An appreciable proportion of older children and adults with mAbs appear to have a low risk of progressing to type 1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better target those most likely to progress.
引用
- Jacobsen LM, Bocchino L, Evans-Molina C, et al. The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia. 2019. PMID: 31768570. doi:10.1007/s00125-019-05047-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。